Research library

A

grade

Teriparatide plus zoledronic acid did not significantly reduce fracture risk in adults with osteogenesis imperfecta compared to standard care, despite increasing bone mineral density.

36.9% of participants in the teriparatide plus zoledronic acid group had incident fractures vs 36.4% in the standard care group, absolute risk reduction -1.57%, 95% CI -9.90% to 5.89%, hazard ratio 0.97, 95% CI 0.68 to 1.38.

summary

C

grade

This study shows that Teriparatide (PTH(1-34)) regulates a significant number of genes in osteoblasts compared to its analogs, but the findings are based on mouse models and may not directly apply to humans.

PTH(1-34) regulated 367 genes, including 194 unique genes.

summary

B

grade

This study identifies key genes and receptors involved in osteoclast differentiation, which could inform future osteoporosis research. However, findings are based on a small sample and in vitro models, limiting direct clinical application.

8446 differentially expressed genes grouped into eight temporal patterns.

summary

C

grade

The response to teriparatide varies significantly by genetic background and sex, which may help explain differing outcomes in human patients. Further research is needed to explore these factors in broader populations.

Not reported in abstract.

summary